ERCC1 and personalized medicine in lung cancer.
ANNALS OF TRANSLATIONAL MEDICINE 2014;
2:32. [PMID:
25333008 DOI:
10.3978/j.issn.2305-5839.2013.12.01]
[Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 08/06/2013] [Accepted: 12/05/2013] [Indexed: 01/16/2023]
Abstract
Excision repair cross-complementing group 1 (ERCC1) is known to be a key player in nucleotide excision repair (NER) pathway. Its prognostic or predictive relevance has been extensively investigated in cancer patients including non-small-cell lung cancer. However, several questions should be addressed before its clinical application as biomarker for patient classification or guiding platinum treatment.
Collapse